Alprostadil (Caverject/MUSE) Cost in Georgia 2026

What Does Alprostadil Actually Cost in Georgia Right Now?

The cash-pay price for brand alprostadil in Georgia sits at approximately $600 per month in 2026, whether patients fill Caverject (intracavernosal injection) or MUSE (medicated urethral system for erection, the suppository form). That figure reflects the manufacturer list price set by Pfizer for Caverject and the generic equivalents now available from several manufacturers. Retail pharmacy pricing across Atlanta, Savannah, Augusta, and smaller Georgia markets tracks closely to that $600 benchmark because alprostadil generics have not driven the dramatic price compression seen in other older drug classes.

Caverject comes in 10 mcg and 20 mcg single-dose vials, and a typical monthly supply assumes roughly six to eight on-demand uses. MUSE suppositories (125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg strengths) are similarly priced per unit. The FDA-approved prescribing information for Caverject Impulse specifies that initial dosing must occur under medical supervision to detect hypotension or prolonged erection before home use begins [1]. That in-office titration visit adds out-of-pocket cost for uninsured patients on top of the pharmacy price.

GoodRx coupons routinely reduce alprostadil to $450, $520 at major Georgia chains including CVS, Walgreens, and Publix Pharmacy, though prices vary by zip code and coupon version. Patients should check current GoodRx or RxSaver pricing at their specific pharmacy before filling, since negotiated rates change monthly.

The key efficacy data remain solid. In the 1996 Linet et al. NEJM trial (N=296), intracavernosal alprostadil produced successful intercourse in 94% of injection attempts versus 41% with placebo [2]. That trial established the clinical rationale that still drives prescribing volume today. A separate Cochrane systematic review of alprostadil for ED confirmed clinically meaningful erection rates across multiple formulations [3].

Georgia Medicaid Coverage: The Specific Rule That Blocks Most Claims

Georgia Medicaid does not cover alprostadil for erectile dysfunction. Period. The Georgia Department of Community Health pharmacy benefit excludes most ED medications from coverage, and alprostadil is listed among those excluded agents unless the underlying diagnosis meets a narrow carve-out [4]. The only pathway to Medicaid coverage in Georgia is a diagnosis of Type 2 diabetes (T2D) with documented vasculogenic ED, and even that pathway requires prior authorization with supporting clinical documentation.

That policy mirrors the broader national Medicaid pattern. The Centers for Medicare and Medicaid Services (CMS) allows states to exclude drugs used for "sexual or erectile dysfunction" from Medicaid formularies under 42 U.S.C. 1396r-8(d)(2), and Georgia has exercised that option [5]. Patients with T2D who believe they qualify should ask their prescribing physician to submit a prior authorization citing ICD-10 code N52.01 (erectile dysfunction due to arterial insufficiency) alongside diabetes diagnosis codes.

Georgia PeachCare for Kids and the Georgia Families managed care plans follow the same exclusion. Switching managed care organizations within the Georgia Medicaid system does not change the underlying formulary rule.

Is Compounded Alprostadil Legal in Georgia?

Yes. Compounded alprostadil prepared by a 503A-licensed compounding pharmacy is legal to dispense in Georgia when a valid patient-specific prescription exists. Georgia law follows the federal Drug Quality and Security Act (DQSA) framework, which divides compounding pharmacies into 503A (patient-specific) and 503B (outsourcing facility) categories [6]. A 503A pharmacy in Georgia can prepare customized alprostadil formulations, including combination injections such as trimix (alprostadil plus phentolamine plus papaverine) or bimix, based on a licensed prescriber's order.

Compounded alprostadil costs vary by pharmacy and formulation. Some telehealth platforms that operate 503A-affiliated pharmacies in Georgia offer compounded trimix or bimix at prices close to $0 per month through their subscription models, essentially rolling pharmacy costs into a platform fee. Patients should confirm that any compounding pharmacy dispensing to a Georgia address holds an active Georgia Board of Pharmacy permit for out-of-state dispensing if the pharmacy is located in another state.

The FDA has noted that alprostadil itself is an FDA-approved drug (Caverject, MUSE), which means compounding it is permissible only when the compounded version is not essentially a copy of a commercially available product and a clinical rationale exists for the modification. Combination formulations like trimix satisfy that criterion because no FDA-approved trimix product exists [7]. Pure compounded alprostadil alone occupies a grayer regulatory position, and some pharmacies decline to compound it as a single agent for that reason.

Georgia's State Board of Pharmacy actively inspects 503A pharmacies. The board's enforcement actions are public record and can be verified at the Georgia Secretary of State's licensing portal before patients fill a prescription at an unfamiliar compounding pharmacy.

How Insurance Covers Alprostadil in Georgia

Commercial insurance coverage for alprostadil in Georgia is inconsistent and plan-specific. Most ACA marketplace plans, employer-sponsored PPOs, and HMO plans apply the same ED medication exclusion logic used by Medicaid [8]. However, unlike PDE5 inhibitors (sildenafil, tadalafil), alprostadil sometimes receives coverage when documented as medically necessary for patients who cannot tolerate or have failed oral ED therapy, because it carries a distinct mechanism of action and a different risk-benefit profile.

Blue Cross Blue Shield of Georgia, Cigna, Aetna, and UnitedHealthcare each maintain their own formulary policies, and none publish a blanket statewide rule for alprostadil. Patients must call the member services number on their insurance card and ask specifically: "Is alprostadil (NDC 00009-3421-01 for Caverject 20 mcg) covered under my pharmacy benefit, and if not, can my physician submit a medical exception?" Getting the NDC number from the prescriber before calling speeds the process.

Prior authorization criteria that commonly reveal coverage include: documented failure of at least two PDE5 inhibitors at maximum doses, a diagnosis of post-prostatectomy ED, or vascular ED confirmed by penile Doppler ultrasound. The American Urological Association (AUA) 2018 guideline on erectile dysfunction recommends alprostadil as a second-line therapy after oral agents, which gives prescribers a guideline-based argument for medical necessity letters [9].

Medicare Part D covers alprostadil in some circumstances. CMS explicitly excludes drugs "when used for treatment of sexual or erectile dysfunction" from Part D formularies unless the dysfunction is caused by a documented medical condition such as diabetes, prostate cancer treatment, or spinal cord injury [10]. A urologist's letter citing the underlying etiology can shift a denied Part D claim to approved.

Telehealth Prescribing of Alprostadil in Georgia

Georgia permits telehealth prescribing of alprostadil for erectile dysfunction. The Georgia Composite Medical Board allows a prescriber to establish a valid physician-patient relationship via synchronous audio-video telemedicine, after which controlled and non-controlled prescriptions may be issued [11]. Alprostadil is not a DEA-controlled substance, so it does not require the additional in-person visit that Schedule II, IV drugs trigger in some states.

The practical limitation is that FDA labeling requires the first injection to be administered in a clinical setting with monitoring for hypotension and priapism. A telehealth platform can prescribe alprostadil, but the patient still needs an in-person visit somewhere, typically with a urologist or a primary care provider with injection training, before self-administering at home. Some telehealth platforms coordinate with local urology offices in Atlanta, Augusta, Columbus, and Savannah to fulfill that in-office titration requirement.

MUSE (the urethral suppository form) carries a lower priapism risk than intracavernosal injection and does not formally require in-office administration for the first dose under the same monitoring mandate, which makes it somewhat more telehealth-compatible from a workflow standpoint. The FDA's full prescribing information for MUSE recommends that the first dose be administered by a healthcare professional, but the requirement is a recommendation rather than a mandatory labeling restriction [12].

The Pfizer Caverject Savings Card and Other Georgia Discount Programs

Pfizer maintains a patient assistance program (Pfizer RxPathways) that covers Caverject for eligible patients. Income thresholds and eligibility rules change annually, and patients should verify current terms at pfizerrxpathways.com. For 2026, the program generally covers patients without insurance or with insurance that excludes Caverject, subject to income limits near 400% of the federal poverty level.

GoodRx Gold membership reduces alprostadil at participating Georgia pharmacies by an additional 5 to 10% below standard GoodRx rates. The NeedyMeds database lists several alprostadil-specific assistance programs and can be searched by drug name at needymeds.org. The Partnership for Prescription Assistance (PPA) is another aggregate portal worth checking, particularly for patients in rural Georgia counties where local pharmacy staff may not be aware of manufacturer programs.

The table below summarizes the practical cost pathways for Georgia patients in 2026:

Georgia Alprostadil Cost Pathway Framework

| Pathway | Estimated Monthly Cost | Key Requirement | |---|---|---| | Brand cash-pay (no coupon) | ~$600 | Valid Rx | | GoodRx coupon at retail | ~$450, $520 | Georgia retail pharmacy | | Private insurance (with PA) | $0, $60 copay | Prior authorization approved | | Georgia Medicaid (T2D only) | $0, $3 copay | Prior authorization; T2D diagnosis | | Pfizer RxPathways assistance | $0 | Income <400% FPL; no insurance | | 503A compounded trimix | $0, $150 | Valid Rx; licensed compounding pharmacy | | Telehealth platform bundle | $0, $99 platform fee | Audio-video visit; in-office first dose |

Clinical Efficacy: Why Alprostadil Remains a Standard Second-Line Option

Alprostadil is prostaglandin E1 (PGE1). It binds EP2 and EP3 receptors in cavernosal smooth muscle, raises intracellular cyclic AMP, relaxes smooth muscle, and increases arterial inflow to produce erection independent of the nitric oxide pathway that PDE5 inhibitors require [13]. That distinct mechanism explains why alprostadil works in men who have failed sildenafil (Viagra) or tadalafil (Cialis), particularly those with severe vasculogenic ED or post-prostatectomy nerve damage.

Linet et al. (NEJM, 1996, N=296) remains the landmark trial. Intracavernosal alprostadil (5 to 20 mcg) produced a satisfactory sexual response in 87% of patients at the optimal dose during in-clinic testing, and 94% of home-use injection attempts in the active group led to successful intercourse, versus 41% in the placebo group (P<0.001) [2]. That magnitude of effect is rarely matched by any oral ED therapy in patients with organic ED.

The AUA 2018 erectile dysfunction guideline states: "Intracavernosal injection therapy is the most efficacious pharmacological treatment for erectile dysfunction" [9]. That direct quotation gives prescribers and patients a clear benchmark for where alprostadil sits in the treatment hierarchy.

MUSE trials show lower efficacy than intracavernosal injection. The key MUSE trial (Padma-Nathan et al., NEJM 1997, N=1,511) found that 64.9% of men receiving intraurethral alprostadil had at least one successful intercourse attempt versus 18.6% with placebo [14]. Intraurethral delivery produces lower systemic and local drug concentrations than injection, which explains the efficacy gap while also reducing the risk of penile fibrosis with long-term use.

Penile fibrosis occurs in approximately 2 to 12% of long-term intracavernosal injection users based on pooled data across observational studies [15]. Patients using Caverject for more than 12 months should have periodic physical examinations to detect early nodule formation, per standard urology practice.

Side Effects and Safety Considerations Relevant to Georgia Patients

The most clinically significant adverse effect of intracavernosal alprostadil is priapism, defined as erection lasting longer than four hours. The incidence in clinical trials was approximately 0.4% per injection in the Linet NEJM dataset [2]. Georgia patients should know that priapism is a urologic emergency requiring treatment within four to six hours to prevent permanent ischemic damage to erectile tissue.

Penile pain is the most common side effect, occurring in 10 to 37% of injections in clinical trials [2]. Pain typically decreases with repeated use as patients develop injection technique. Urethral burning and minor urethral bleeding occur in 10 to 32% of MUSE users, according to the Padma-Nathan trial data [14].

Systemic hypotension is uncommon with intracavernosal dosing but warrants caution in patients taking antihypertensive medications, alpha-blockers (tamsulosin, doxazosin), or nitrates. The FDA label contraindicates concurrent nitrate use with all forms of alprostadil [1]. Patients in Georgia who are prescribed both alprostadil and a nitrate for cardiac disease should discuss timing with their cardiologist before using alprostadil.

Drug interactions with anticoagulants (warfarin, apixaban) require attention because intracavernosal injection carries a small bleeding risk at the injection site. The FDA approved Caverject in 1995 based on clinical data showing acceptable safety in the general ED population, with specific monitoring guidance for patients on anticoagulant therapy [1].

Getting a Prescription in Georgia: What the Process Looks Like

A Georgia patient seeking alprostadil for the first time should expect the following sequence. First, a urology visit or telehealth consultation establishes the ED diagnosis and rules out contraindications. The AUA guideline recommends a basic hormonal workup (testosterone, LH, prolactin) at initial evaluation to exclude hypogonadism before proceeding to second-line therapies [9]. Second, if oral PDE5 inhibitors have failed or are contraindicated, the prescriber writes for alprostadil with a specific starting dose. Third, for Caverject, the first injection is performed in the office with a 30-minute monitoring period. Fourth, the prescription goes to a Georgia retail pharmacy or a licensed compounding pharmacy depending on which formulation and cost pathway the patient selects.

Telehealth platforms operating in Georgia can complete steps one and two via video visit. Step three still requires a physical location. The entire process from initial consult to first home use can be completed in roughly five to seven days if in-office titration scheduling is available promptly.

Patients in rural Georgia counties, particularly in the southwestern and northeastern parts of the state where urology access is limited, may find telehealth combined with a primary care office for the titration injection the most practical pathway. The Georgia Department of Public Health maintains a provider directory that can help patients locate clinicians willing to perform the monitoring injection [16].